With the support of the COVID-19 Vaccine Composition Technical Advisory Group (TAG-CO-VAC) and the World Health Organization (WHO), the Strategic Advisory Group on Immunization (SAGE), two statements he insisted that vaccines protect against “serious” illness and “death” in all variants.
“Priority remains achieve high coverage rates with primary series and booster doses In the highest usage groups and high priority in all countries,” the agency warned that new variants are expected to emerge.
In addition, the inclusion of omicron in a modified vaccine composition administered as a booster is expected to become widespread. immunity while protecting against serious illness and death.
Approval by a WHO emergency use list or a strict regulatory authority of a vaccine product with a modified composition will allow SAGE to provide policy recommendations for its use.
main purpose of vaccination COVID-19 reduce hospitalizations, serious illness, and death.and protecting health systems. The use of currently licensed vaccines based on the index virus (i.e. the virus identified from the first COVID-19 cases in December 2019) provides a high level of protection against serious disease outcomes for all variants, including booster micron. dose.
Is there a Ongoing and significant evolution of the virus since the emergence of SARS-CoV-2 in late 2019and this evolution is likely to continue, resulting in the emergence of new variants, particularly those with changes in the spike protein. The evolutionary trajectory of SARS-CoV-2 remains unclear, and the characteristics of future variants cannot yet be predicted.
“Given these uncertainties, it may be prudent to pursue an additional COVID-19 vaccination target to achieve broader immunity against circulating and emerging variants while maintaining protection against serious illness and death,” WHO said. Said.
Available data suggest that the inclusion of omicron, the most antigenically distinct SARS-CoV-2 variant of concern, in an updated vaccine composition could be beneficial if given as a booster dose to those who have already received a series of primary vaccines against COVID. -19.
On your own behalf European Medicines Agency (EMA, for English acronym) a ongoing review of a version of the vaccine modern against COVID-19, adapted to provide better protection against variants of the virus.
The review focuses Bivalent vaccine developed by Modernaand targeting two strains of SARS-CoV-2, in this case the original strain and the omicron variant.
The EMA analysis will initially focus on data from laboratory studies (non-clinical data) and data on chemistry, manufacturing and controls referring to the manufacture of the vaccine. As Moderna progresses in the development of the bivalent vaccine, the EMA will receive more data, including data on the immune response to the parent strain and the omicron variant.
When initiating a continuous review, EMA will be able to evaluate these data as they become available.. The investigation will continue until sufficient data is available for Moderna to make an official authorization request.
In any case, the composition of vaccines adapted to the new variants will ultimately depend on recommendations from public health officials and the World Health Organization (WHO), as well as assessments by regulatory bodies such as the EMA and other members. International Coalition of Drug Regulatory Authorities (ICMRA).